Tamas Masztis from Kite discusses his career and the top trends in cell therapy:

We interview Tamas Masztis, Senior Director, Cell Therapy Supply Chain for Europe, Kite, a Gilead Company. Tamas built one of the first cell therapy supply chains for Europe and Israel. The successful implementation of this complex, centralised end-to-end supply chain involving the transportation of patient cells has been critical to launching Kite’s cell therapies in 24 countries in the region to date.

In part 1 of this interview, we find out more about Tamas’ career and work at the company.

In part 2 of this interview, Tamas discusses the biggest supply chain challenges for cell therapies, the impact of the pandemic, and where the industry’s priorities need to lie in the coming years.

Tamas was recently a speaker at Advanced Therapies Integrates on the “Skills: The global gold rush” panel